Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026)
Theravance Biopharma (TBPH) reported Cash from Operations of 73279000.0 for Q1 2026, up 70.26% year-over-year from 43039000.0 in Q1 2025, and up 1308.43% quarter-over-quarter from 6064000.0 in Q4 2025.
Theravance Biopharma (TBPH) Cash from Operations (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has 14 years of Cash from Operations data on file, last reported at 73279000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 73279000.0, up 70.26% year-over-year; the trailing twelve-month figure through Mar 2026 was 268781000.0 (up 726.36% YoY), and the FY2025 annual result was 238541000.0, up 2167.98% from the prior year.
- Cash from Operations improved to 73279000.0 in Q1 2026 per TBPH's latest filing, from 6064000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 208074000.0 in Q2 2025 and troughed at 124055000.0 in Q4 2022.
- A 5-year average of 5076294.12 and a median of 5196000.0 in 2024 frame the typical range for Cash from Operations.
- On a YoY basis, Cash from Operations climbed as much as 4812.89% in 2025 and fell as far as 572.28% in 2025.
- A 5-year view of Cash from Operations shows it stood at 124055000.0 in 2022, then soared by 99.31% to 854000.0 in 2023, then declined by 5.62% to 902000.0 in 2024, then tumbled by 572.28% to 6064000.0 in 2025, then surged by 1308.43% to 73279000.0 in 2026.
- Business Quant data shows TBPH's Cash from Operations at 73279000.0 in Q1 2026, 6064000.0 in Q4 2025, and 6508000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Theravance Biopharma | 835.85 Mn | 441.18 Mn | - | 73.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.28 Mn |
| Mar 31, 2026 | 73.28 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Dec 31, 2025 | -6.06 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Sep 30, 2025 | -6.51 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Jun 30, 2025 | 208.07 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Mar 31, 2025 | 43.04 Mn |
| Dec 31, 2024 | -902,000.00 |
| Dec 31, 2024 | -902,000.00 |
| Sep 30, 2024 | -5.20 Mn |
| Sep 30, 2024 | -5.20 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Dec 31, 2023 | -854,000.00 |
| Dec 31, 2023 | -854,000.00 |